Asthma Management Guidelines

Assessment and Classification

• Asthma severity can be classified into four categories: intermittent, mild persistent, moderate persistent, and severe persistent, based on symptoms and nighttime awakenings 1

Treatment Approach

• The American Thoracic Society recommends a stepwise approach for asthma management, with inhaled corticosteroids (ICS) as the most effective controller medication for persistent asthma at all steps of care 1
• The National Asthma Education and Prevention Program recommends adjusting treatment based on the level of asthma control, with step-up or step-down therapy as needed 1
• The American Academy of Allergy, Asthma, and Immunology recommends regularly assessing and demonstrating proper inhaler technique to ensure effective treatment 1

Medication and Dosing

• For mild persistent asthma, the preferred treatment is low-dose ICS, with examples including fluticasone HFA 88-264 mcg/day and budesonide DPI 180-600 mcg/day 1
• For moderate persistent asthma, the preferred treatment is low-dose ICS plus LABA or medium-dose ICS, with examples including fluticasone/salmeterol 100/50 mcg or 250/50 mcg, 1 inhalation twice daily 1
• For severe persistent asthma, the preferred treatment is high-dose ICS plus LABA, with examples including fluticasone HFA >440 mcg/day and budesonide DPI >1200 mcg/day 1
• Oral corticosteroids, such as prednisolone 30-60 mg daily, may be considered for patients with severe asthma 2

Assessment and Monitoring

• Asthma control should be assessed at 2-6 week intervals initially, then every 1-6 months, with consideration of step-down therapy if control is maintained for at least 3 months 1
• Monitor peak expiratory flow to guide therapy adjustments, as stated by the European Respiratory Society 2

Exacerbation Management

• For severe exacerbations, treatment may include high-dose beta-agonist via nebulizer or multiple actuations of MDI with spacer, systemic steroids, and ipratropium nebulized 2
• Systemic Corticosteroids: used for moderate to severe exacerbations, with short courses (5-10 days) to gain prompt control, as stated by the American College of Allergy, Asthma, and Immunology 1

Safety and Efficacy

• Low-to-medium dose ICS may be associated with approximately 1 cm reduction in growth velocity, but the benefits of ICS generally outweigh potential growth effects 1
• The American College of Allergy, Asthma, and Immunology recommends using the lowest effective dose of ICS and monitoring growth in children 1

Medication Options

• Inhaled Corticosteroids (ICS): first-line therapy for persistent asthma, with examples including fluticasone propionate and budesonide, which reduce airway hyperresponsiveness and inhibit inflammatory cell migration and activation, as stated by the American Thoracic Society 1
• Long-Acting Beta2-Agonists (LABAs): not to be used as monotherapy, but rather combined with ICS, with examples including salmeterol and formoterol, used as preferred combination therapy with ICS for moderate and severe persistent asthma, according to the American Academy of Family Physicians 3
• Leukotriene Modifiers: alternative therapy for mild persistent asthma, with examples including montelukast and zafirlukast, which can be used as adjunctive therapy with ICS for moderate persistent asthma, as recommended by the American College of Allergy, Asthma, and Immunology 1
• Cromolyn Sodium and Nedocromil: alternative medications for mild persistent asthma, which stabilize mast cells and interfere with chloride channel function, and can be used as preventive treatment before exercise or allergen exposure, according to the American Academy of Allergy, Asthma, and Immunology 1
• Immunomodulators: omalizumab (anti-IgE) is used as adjunctive therapy for patients ≥12 years with severe persistent asthma and sensitivity to relevant allergens, as stated by the American College of Allergy, Asthma, and Immunology 1
• Methylxanthines (Theophylline): alternative therapy for mild persistent asthma, which requires monitoring of serum levels, according to the American Academy of Family Physicians 3
• Short-Acting Beta2-Agonists (SABAs): primary rescue medication for acute symptom relief, with examples including albuterol and levalbuterol, used as needed for all severity levels, as recommended by the American Academy of Family Physicians 3
• Anticholinergics: example includes ipratropium bromide, which can be used as adjunctive therapy with SABAs for severe exacerbations, according to the European Respiratory Society 2

Stepwise Approach for Asthma Management

Common Pitfalls in Asthma Management

• Overreliance on SABAs: if using more than one canister per month, daily controller therapy should be increased, according to the American Academy of Family Physicians 3
• Underuse of ICS: many patients underuse controller medications and overuse rescue medications, as stated by the American College of Allergy, Asthma, and Immunology 1
• Poor inhaler technique: ensure proper inhaler technique through demonstration and regular assessment, according to the American Academy of Family Physicians 3
• Lack of written asthma action plan: all patients should have a written plan for managing exacerbations, as recommended by the American Academy of Family Physicians 3
• Failure to address comorbidities: conditions like allergic rhinitis, sinusitis, and GERD can worsen asthma control and should be treated, according to the American College of Allergy, Asthma, and Immunology 1